Personalized medicine

South Africa Biopharmaceuticals Market Outlook & Forecast Report 2023-2028: Push for Local Biopharmaceutical Production Attracts Global Interest - ResearchAndMarkets.com

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Pharmaceutical, Health, WHO, Anthrax Vaccine Immunization Program, Biomedical Research, Ageing, Strategic planning, Rare, Vaccine, Therapy, Prevalence, Conditional sentence, Research, ART, Quality of life, Growth, Life expectancy, A-DNA, Personalized medicine, Medicine, HIV/AIDS, Economic development, Hormone, Infection, Public, Patient, Fine chemical, Pharmaceutical industry, Health care, African

The "South Africa Biopharmaceuticals Market - Industry Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "South Africa Biopharmaceuticals Market - Industry Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • South Africa is showing promising signs of local biopharmaceutical production, reflecting a strong interest in developing a self-sufficient pharmaceutical industry.
  • Promoting local production in the South Africa biopharmaceuticals market can enhance access to essential medicines, drive healthcare innovation, and contribute to economic development, ultimately benefiting the healthcare sector and the population's well-being.
  • The growing South Africa biopharmaceuticals market offers attractive investment opportunities for companies and investors.

Labroots Announces Agenda for its 14th Annual Clinical Diagnostics & Research Online Event - held on November 8th, 2023

Retrieved on: 
Monday, November 6, 2023
Linda, TBI, Q&A, Pathology, Medical laboratory, Clinical professor, Workplace, Research, Sartorius, Dietary supplement, Mass spectrometry, Ortho Clinical Diagnostics, Roche, Networking hardware, Medicine, Labroots, Greeting, LR, Personalized medicine, Melissa Chaty, Thermo Fisher Scientific, Diversity, Lab, Patient, Mayo Clinic, Medical device, Nursing, News, Clinical

YORBA LINDA, Calif., Nov. 6, 2023 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 14th annual event in the Clinical Diagnostics & Research Virtual Event Series scheduled on November 8, 2023. This event will continue its long-standing commitment to advance clinical diagnostics, novel research and medicine, and to align research scholars, clinicians, top scientists, healthcare professionals and experts from leading academia and industry institutions under a virtual roof on a global basis.

Key Points: 
  • YORBA LINDA, Calif., Nov. 6, 2023 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 14th annual event in the Clinical Diagnostics & Research Virtual Event Series scheduled on November 8, 2023.
  • Attendees will also see multiple panels and presentations from key industry sponsors including, Sartorius, Thermo Fisher Scientific, and Roche Diagnostics.
  • Use the hashtag #LRclinical to follow the conversation and connect with other members of the global Clinical & Molecular Dx Community!
  • Join our Clinical & Molecular Dx Interest Group on LinkedIn to connect with us, and the wider professional community!

How AI is Transforming Drug Discovery: Bio-IT World Europe Participants to Share Groundbreaking Advances 29-30 November in London

Retrieved on: 
Monday, November 6, 2023
Digital, China Earthquake Networks Center, AstraZeneca, Expert system, Health care, Government, LDN, Conference, Organization, Research, Drug development, Clarivate, Artificial intelligence, MOSAIC, Medicine, Drug discovery, Machine learning, Personalized medicine, RDN, AI, Potential, D, Queen Mary University of London, Medical device, Cancer

LONDON, Nov. 6, 2023 /PRNewswire-PRWeb/ -- The life sciences profession is in the midst of a profound transformation, guided by the revolutionary force of artificial intelligence (AI), and especially predictive and generative AI models. These state-of-the-art technologies are leading the charge—expediting drug discovery and development, catalyzing innovation, and uncovering potential new therapies for cancer, heart disease, and more.

Key Points: 
  • These state-of-the-art technologies are leading the charge—expediting drug discovery and development, catalyzing innovation, and uncovering potential new therapies for cancer, heart disease, and more.
  • "The bio-IT community has always been at the forefront of leveraging AI with the important goal of increasing therapeutic efficacy."
  • In parallel, generative AI refines molecular design with exquisite precision, drastically curtailing the time and resources necessary for drug development.
  • "As general interest in AI explodes, our distinguished speakers have valuable information to share about its evolving role in precision medicine."

Dynami Funds New Groundbreaking Research for Lobular Breast Cancer

Retrieved on: 
Wednesday, November 1, 2023
Dean (education), Karmanos Cancer Institute, Biomarker, Leigh, Doctor of Philosophy, Disease, Risk, Partnership, DRS, University of Michigan, UPMC, Fertility preservation, Hope, Physician, Hereditary lobular breast cancer, Impact, University of Pittsburgh Medical Center, IVF, Breast cancer, University, Morávek, Cancer, Patient, Biomedical engineering, ILC, University of Colorado, History, MD, Work, Woman, University of Colorado School of Medicine, Black, Multimedia, Recurrence, Personalized medicine, United States and Canadian Academy of Pathology, Medical device, Vaccine, Medical imaging, Birth control, Pharmaceutical industry, Research, Pathology, Pharmacology, Dynamy

DETROIT, Nov. 1, 2023 /PRNewswire/ -- The Dynami Foundation has funded groundbreaking new research and support for lobular breast cancer through their partnership with University of Michigan Health. Recently released University of Michigan Health Impact Report outlines the progress and work made possible by the Dynami Foundation's initiatives that are focused on transforming the future of invasive lobular breast cancer (ILC) through the funding of research.

Key Points: 
  • DETROIT, Nov. 1, 2023 /PRNewswire/ -- The Dynami Foundation has funded groundbreaking new research and support for lobular breast cancer through their partnership with University of Michigan Health.
  • From groundbreaking new research on circulating cells to a dual-institution effort to combat cancer, Dynami and University of Michigan have partnered to drive progress.
  • A patient-centered decision-making process by understanding goals of lobular breast cancer patients for an elevated, personalized breast reconstruction experience led by Dr. Paige Myers.
  • Dynami has funded over 12 research projects and will continue to fight for advancement for lobular breast cancer just like the incredible work and impact that we've made here."

LUNGevity Foundation's No One Missed Campaign Commemorates Third Year of #KnowYourBiomarker Storytelling Initiative

Retrieved on: 
Wednesday, November 1, 2023
Aurora, Insurance, NSCLC, Cancer Support Community, Lung cancer, Wellstar Health System, Organization, Hope, Northside Hospital, ALK, Research, Progress, Chest pain, Disease, Winship Cancer Institute, NED, Radiation, Emory University, Biopsy, CT, X-ray, Immunotherapy, Personalized medicine, Fertility preservation, Cancer, Patient, Diagnosis, Prognosis, Mutation, EGFR, Medical imaging, Atlanta

WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit, today celebrates the third year of #KnowYourBiomarker, a social media initiative that highlights the stories of people living well with lung cancer. The initiative is part of LUNGevity's No One Missed campaign aimed at driving awareness of comprehensive biomarker testing in non-small cell lung cancer (NSCLC).

Key Points: 
  • She started chemotherapy, which resulted in awful side effects that prevented her from being able to work.
  • After her healthcare team ordered biomarker testing, they discovered her cancer was positive for the ALK mutation and matched Shirley with a targeted therapy.
  • Now, three years after her diagnosis, Shirley is living her life to the fullest.
  • In addition to No One Missed's #KnowYourBiomarker initiative, LUNGevity has other ways to get involved during Lung Cancer Awareness Month.

Global Molecular Cytogenetics Market Research Report 2023: Rising Adoption of Array Based CGH to Spur Overall Demand - Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 26, 2023
Research, Science, Age, Developed country, Growth, Genetic, Personalized medicine, Prevalence, Development, Incidence, Software, Genetic disorder, Fluorescence in situ hybridization, Fluorescence, Comparative genomic hybridization, Real, COVID-19, CGH, Molecular Cytogenetics, Molecular biology, Abbott Laboratories, Thermo Fisher Scientific, Total, Table, Cornerstone, Consumables, Fine chemical, Retail, Agriculture, Tourism, Video game, Karyotype, Immunohistochemistry, Revenue, Cancer, Instrument

The "Molecular Cytogenetics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Cytogenetics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • This market encompasses various facets, including Molecular Cytogenetics itself, Consumables, Instruments, Software & Services, as well as techniques like CGH (Comparative Genomic Hybridization), FISH (Fluorescence In Situ Hybridization), Immunohistochemistry, Karyotyping, and other methods.
  • The U.S. market, with an estimated worth of US$794.6 million in 2022, holds a prominent position within this market.
  • This report provides an extensive analysis of the global Molecular Cytogenetics market, furnishing insights into annual revenues, historical patterns, and future forecasts spanning from 2014 to 2030.

Veterinary Diagnostic Market Worth $5.0 billion | MarketsandMarkets

Retrieved on: 
Thursday, October 26, 2023
Research, Dermatology, Pet, Health, Veterinary medicine, PIMS, Risk, Telehealth, Partnership, Thermo Fisher Scientific, Public, AI, Infection, Microfluidics, Veterinarian, Idexx Laboratories, Cat, Acquisition, Milk, University, American Pet Products Association, Dog, Patient, Randox, POC, FEC, Research and development, Animal, Fujifilm, Communication, UK Rapid Test Consortium, Laboratory, Parasitism, Livestock, Disease, Vaccination, Science, Personalized medicine, Pet industry, Medical device, Vaccine, Medical imaging

The veterinary diagnostics market is divided into companion animals and livestock in the animal type segment.

Key Points: 
  • The veterinary diagnostics market is divided into companion animals and livestock in the animal type segment.
  • Key Market Players of Veterinary Diagnostic Industry:
    The veterinary diagnostics market is a consolidated market with the presence of few dominant multinational market players.
  • Research and Development: Ongoing innovations in diagnostic technologies contribute to the advancement of veterinary medicine and drive further research in animal health.
  • Economic Benefits: Timely and accurate diagnostics can reduce healthcare costs and losses in livestock and agricultural settings, making the veterinary diagnostic market economically advantageous for various stakeholders.

Veterinary Diagnostic Market Worth $5.0 billion | MarketsandMarkets

Retrieved on: 
Thursday, October 26, 2023
Research, Dermatology, Pet, Health, Veterinary medicine, PIMS, Risk, Telehealth, Partnership, Thermo Fisher Scientific, Public, AI, Infection, Microfluidics, Veterinarian, Idexx Laboratories, Cat, Acquisition, Milk, University, American Pet Products Association, Dog, Patient, Randox, POC, FEC, Research and development, Animal, Fujifilm, Communication, UK Rapid Test Consortium, Laboratory, Parasitism, Livestock, Disease, Vaccination, Science, Personalized medicine, Pet industry, Medical device, Vaccine, Medical imaging

The veterinary diagnostics market is divided into companion animals and livestock in the animal type segment.

Key Points: 
  • The veterinary diagnostics market is divided into companion animals and livestock in the animal type segment.
  • Key Market Players of Veterinary Diagnostic Industry:
    The veterinary diagnostics market is a consolidated market with the presence of few dominant multinational market players.
  • Research and Development: Ongoing innovations in diagnostic technologies contribute to the advancement of veterinary medicine and drive further research in animal health.
  • Economic Benefits: Timely and accurate diagnostics can reduce healthcare costs and losses in livestock and agricultural settings, making the veterinary diagnostic market economically advantageous for various stakeholders.

The Caris Precision Oncology Alliance Welcomes Sarah Cannon Research Institute

Retrieved on: 
Thursday, October 26, 2023
FDA, Intelligence, Physician, Personalized medicine, SCRI, MD, Doctor of Philosophy, MBA, POA, Database, Sarah Cannon Research Institute, Medicine, Machine learning, FACP, Cancer, Patient, Pharmaceutical industry, Medical imaging

IRVING, Texas, Oct. 26, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced today that Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, has joined the Caris Precision Oncology Alliance™ (POA).

Key Points: 
  • IRVING, Texas, Oct. 26, 2023 /PRNewswire/ -- Caris Life Sciences ®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced today that Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, has joined the Caris Precision Oncology Alliance™ (POA).
  • SCRI, a global leader in oncology research, has conducted clinical trials in the community for more than 30 years.
  • Their contributions to pivotal research helped to advance the majority of new cancer therapies approved by the FDA today.
  • "We are pleased to join the Caris Precision Oncology Alliance, and look forward to the opportunities to leverage comprehensive genomic data to inform clinical development strategies to improve outcomes for people facing cancer."

October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology

Retrieved on: 
Friday, October 20, 2023
Science, Survival, FDA, University of Pittsburgh School of Medicine, Associate, Clinical professor, Life, Internet, Lung cancer, Literature, Physician, Mortality, News, Doctor of Philosophy, Breast Cancer Awareness Month, Breast cancer, CPI, TNBC, ClinicalTrials.gov, Trust, Letter, Life expectancy, Disease, Risk, Partnership, University of Pittsburgh, Personalized medicine, Immunotherapy, University, Sandra, Figure, Woman, Wilfrid Sellars, Fast track (FDA), FACP, Cancer, Therapy, BCT, Weill Cornell Medicine, Diagnosis, Patient, TSX, Mayo Clinic, Liquor, Pharmaceutical industry, Birth control, Medical imaging, MD

The overall risk of a woman in the United States developing breast cancer sometime in her life is about 13%.

Key Points: 
  • The overall risk of a woman in the United States developing breast cancer sometime in her life is about 13%.
  • This means there is an approximately 1 in 8 chance she will develop breast cancer;
    Approximately 43,170 women and 530 men are expected to die of breast cancer in the U.S. in 2023, making breast cancer the 2nd leading cause of cancer death in women (after lung cancer) in the U.S.
  • I am writing this letter during Breast Cancer Awareness month to alert all to the devastation of advanced breast cancer.
  • While the focus of the month is on early detection, as it should be, I highlight our recent accomplishments in the fight against advanced breast cancer, an incurable disease.